Skip to content
    ABOS
    Earnings call· Jun 2026(Q2 FY26)

    Acumen Pharmaceuticals Q2 FY26 earnings call ABOS

    Aug 12, 2026 Source

    Executive summary

    Acumen Q2 FY26 — Phase II ALTITUDE-AD Readout Expected Late 2026; EBD Program Advances

    Acumen Pharmaceuticals remains focused on advancing sabirnetug towards its critical Phase II ALTITUDE-AD topline readout expected late this year, which will test the central scientific thesis of selectively targeting amyloid-beta oligomers. The company also progressed its enhanced brain delivery program with two nominated candidates, ACU301 and ACU401, aiming for an IND filing in mid-2027, expanding pipeline optionality.

    Highlights

    3

    • Ended Q2 FY26 with $110.2 million in cash and marketable securities, expected to support activities into early 2027.

    • Nominated two enhanced brain delivery (EBD) candidates, ACU301 and ACU401, with ACU401 achieving up to 40-fold greater frontal cortex exposure in non-human primates.

    • Phase I results for sabirnetug demonstrated robust clinical target engagement of A-beta oligomers and biomarker changes as early as 3 months.

    Concerns

    2

    • Reported a net loss of $32.7 million in Q2 FY26.

    • Experienced a loss from operations of $32.6 million in Q2 FY26.

    Guidance & targets

    4
    CategoryTargetConfidence
    Phase II ALTITUDE-AD topline readout
    Late this year
    high materiality
    High
    Lead EBD candidate IND filing
    Mid-2027
    medium materiality
    High
    Cash runway
    Into early 2027
    high materiality
    High
    Investor Relations Day
    September 16
    low materiality
    High

    Operational metrics

    6
    Cash and marketable securities
    $110.2M
    Q2 FY26

    Balance on the balance sheet at the end of the second quarter.

    R&D expenses
    $27.8Mdecrease over prior year
    Q2 FY26

    Primarily due to reductions in manufacturing and materials costs as well as CRO costs as the clinical trial nears completion.

    G&A expenses
    $4.7Mroughly flat for the same period in the prior year
    Q2 FY26

    General and administrative expenses for the second quarter.

    Loss from operations
    $32.6M
    Q2 FY26

    Operating loss for the second quarter.

    Net loss
    $32.7M
    Q2 FY26

    Net loss for the second quarter.

    ACU401 frontal cortex exposure
    up to 40-fold greatervs unmodified ACU234 alone
    Preclinical

    ACU401 achieved significantly increased exposure in deep brain regions in cynomolgus monkeys.

    Industry KPIs

    2
    MetricValueDetails
    Pipeline read out calendarPhase II ALTITUDE-AD topline readout
    Regulatory approvals filingsIND filing for lead EBD candidate

    Deals & partnerships

    1
    JCR PharmaceuticalsCollaboration for blood-brain barrier penetrating technology

    Acumen exercised its options with JCR Pharmaceuticals to advance two enhanced brain delivery candidates, ACU301 and ACU401, leveraging robust preclinical data from their blood-brain barrier penetrating technology.

    Risks & headwinds

    2
    Clinical trial failure or delayed regulatory decisionsLate 2026 (ALTITUDE-AD readout)

    Not quantified

    Mitigation: Disciplined execution of Phase II ALTITUDE-AD trial; well-designed study to validate oligomer hypothesis; focus on differentiated benefit-to-risk profile of sabirnetug.

    Competitive landscape and market adoptionOngoing

    Not quantified

    Mitigation: Focus on sabirnetug's unique product attributes (anti-A-beta oligomer IgG2 monoclonal) for a differentiated benefit-to-risk profile; evaluating combination strategies with other therapeutic approaches (tau, anti-inflammatory).

    What to watch in Q3 FY26

    4

    Sabirnetug Phase II ALTITUDE-AD topline readout

    Late 2026
    CurrentExpected late this year
    TargetRelease of primary endpoint (iADRS), secondary measures (CDR-SB), safety (ARIA rates), and biomarker data

    Why it matters

    This is the landmark catalyst testing the core scientific thesis and will determine the future clinical path of sabirnetug.

    During the second quarter, our focus remained on disciplined execution as we advanced sabirnetug towards the highly anticipated topline readout from our Phase II ALTITUDE-AD trial, which we continue to expect late this year.

    Q&A highlights

    10

    How does Acumen's oligomer-specific approach differ from competitors like Kisunla and Leqembi, and what are the safety expectations given their real-world experience?

    Acumen's approach targets A-beta oligomers, which is differentiated from plaque-targeting antibodies. Sabirnetug is an IgG2 antibody, which has less effector function compared to IgG1 antibodies (like competitors), potentially leading to a better safety profile, especially regarding ARIA rates. Phase I data showed robust target engagement.

    “So there's two reasons to think that our safety and tolerability could be quite good. One is that we have this differentiated target, oligomers, and the second is that we have an IgG2 antibody with less effector function and less immune system activation.”

    asked by Matthew Ryan Tan · answered by Eric Siemers

    2 min read5 chapters

    Detailed Narrative

    01

    ALTITUDE-AD Phase II Progress and Design

    Acumen remains focused on disciplined execution for the sabirnetug Phase II ALTITUDE-AD trial, with topline readout expected late this year. The study is designed to detect a statistically significant difference on its primary clinical efficacy endpoint, iADRS, after 18 months of treatment with sabirnetug compared with placebo. It evaluates two dose levels, 35 mg/kg and 50 mg/kg, both within the exposure range previously shown to achieve pharmacodynamic target engagement. The topline dataset will include results from the primary endpoint, key secondary measures like CDR-SB, safety assessments including ARIA rates, and important fluid and imaging biomarkers.

    02

    Advancement of Enhanced Brain Delivery (EBD) Program

    The company announced the nomination of two enhanced brain delivery (EBD) candidates, ACU301 and ACU401, for Alzheimer's disease. This program combines a validated blood-brain barrier penetrating technology with an anti-A-beta oligomer-selective therapeutic antibody, building on preclinical data. ACU301 is a bispecific antibody incorporating sabirnetug, while ACU401 incorporates a novel next-generation A-beta oligomer-selective antibody (ACU234). ACU401 achieved up to a 40-fold greater frontal cortex exposure in non-human primates, and an IND filing for the lead EBD candidate is anticipated in mid-2027.

    03

    Biomarker Strategy and Future Exploration

    Acumen utilizes p-tau217 as part of its screening procedure for ALTITUDE-AD and will also evaluate it as an outcome measure. While MTBR-tau243 was not included in the initial ALTITUDE-AD design, the company stores plasma samples, providing the opportunity to explore newer blood-based biomarkers post-study completion. Management believes these fluid-based biomarkers are crucial for understanding disease progression and potentially identifying patients who might be better candidates for treatment in the future.

    04

    Leveraging Digital Twins for Trial Optimization

    Acumen has partnered with Unlearn.AI to incorporate digital twins as an exploratory endpoint in the ALTITUDE-AD study. These digital models rely on data from thousands of patients to predict individual disease progression over time⏳. The company is evaluating how these tools can be used to refine patient selection, serve as a prognostic covariate in analyses, and potentially optimize future trial designs, aiming to understand their value for future applications.

    05

    Financial Overview and Cash Runway

    Acumen ended the second quarter of 2026 with $110.2 million in cash and marketable securities, which is expected to support current clinical and operational activities into early 2027. R&D expenses were $27.8 million in the second quarter, a decrease from the prior year primarily due to reductions in manufacturing and CRO costs as the clinical trial progresses. G&A expenses remained relatively flat at $4.7 million, leading to a net loss of $32.7 million for the quarter.

    AI-generated summary of the company’s earnings call. Not investment advice.